
Annual report 2024
added 01-17-2026
Cellectis S.A. Net Debt 2011-2026 | CLLS
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt Cellectis S.A.
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| - | -206 M | -293 M | -450 M | -256 M | -252 M | -342 M | -132 M | -4.82 M | -23.2 M | 14.1 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 14.1 M | -450 M | -194 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Biotechnology industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
163 M | - | 2.43 % | $ 254 M | ||
|
ARCA biopharma
ABIO
|
-60.6 M | - | 1052.0 % | $ 415 M | ||
|
Adagene
ADAG
|
-71 M | $ 2.4 | -3.61 % | $ 135 M | ||
|
Acorda Therapeutics
ACOR
|
114 M | - | -24.86 % | $ 820 K | ||
|
BioNTech SE
BNTX
|
-973 M | $ 117.62 | 1.41 % | $ 27.2 B | ||
|
Aptorum Group Limited
APM
|
-2.77 M | $ 0.98 | 1.35 % | $ 5.34 M | ||
|
Acasti Pharma
ACST
|
-27.4 M | - | 4.01 % | $ 150 M | ||
|
Alterity Therapeutics Limited
ATHE
|
-34.7 M | $ 3.67 | 3.38 % | $ 8.83 B | ||
|
Aeglea BioTherapeutics
AGLE
|
-30.2 M | - | - | $ 1.01 B | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
-402 M | - | - | $ 40.3 B | ||
|
Biophytis SA
BPTS
|
-4.01 M | - | -13.47 % | $ 169 M | ||
|
Aptose Biosciences
APTO
|
-5.53 M | - | -45.71 % | $ 1.2 M | ||
|
Aravive
ARAV
|
-49.6 M | - | -13.39 % | $ 1.45 M | ||
|
Athira Pharma
ATHA
|
-47.2 M | - | - | $ 269 M | ||
|
Midatech Pharma plc
MTP
|
-6.17 M | - | -18.52 % | $ 27.3 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
-824 K | - | -1.52 % | $ 24.7 M | ||
|
AVROBIO
AVRO
|
-76.6 M | - | 1083.1 % | $ 745 M | ||
|
Akero Therapeutics
AKRO
|
-340 M | - | - | $ 3.67 B | ||
|
Aytu BioScience
AYTU
|
-19.9 M | $ 2.75 | 1.85 % | $ 17.3 M | ||
|
Brickell Biotech
BBI
|
-29.7 M | - | -5.38 % | $ 6.06 M | ||
|
Biogen
BIIB
|
4.01 B | $ 173.17 | 0.92 % | $ 25.2 B | ||
|
Bellicum Pharmaceuticals
BLCM
|
-34.7 M | - | -9.72 % | $ 5.89 M | ||
|
BioLineRx Ltd.
BLRX
|
-13.9 M | $ 3.12 | 0.59 % | $ 908 M | ||
|
Applied Molecular Transport
AMTI
|
-56.5 M | - | - | $ 10.1 M | ||
|
Институт стволовых клеток человека
ISKJ
|
246 M | - | - | - | ||
|
Ascendis Pharma A/S
ASND
|
-195 M | $ 233.49 | -0.81 % | $ 5 B | ||
|
BioXcel Therapeutics
BTAI
|
73 M | $ 1.77 | -2.75 % | $ 4.49 M | ||
|
Calithera Biosciences
CALA
|
-56.5 M | - | -10.95 % | $ 876 K | ||
|
Burford Capital Limited
BUR
|
-135 M | $ 9.71 | -0.46 % | $ 1.57 B | ||
|
CASI Pharmaceuticals
CASI
|
-36.5 M | $ 0.99 | 2.79 % | $ 135 M | ||
|
Catalyst Biosciences
CBIO
|
-33.1 M | $ 11.66 | -8.95 % | $ 768 M | ||
|
Arrowhead Pharmaceuticals
ARWR
|
-115 M | $ 67.41 | 0.54 % | $ 9.02 B | ||
|
Can-Fite BioPharma Ltd.
CANF
|
-3.5 M | $ 4.36 | -2.46 % | $ 9.49 B | ||
|
Aeterna Zentaris
AEZS
|
-65.1 M | - | 5.93 % | $ 314 M | ||
|
Avid Bioservices
CDMO
|
17.5 M | - | - | $ 789 M | ||
|
AgeX Therapeutics
AGE
|
12.6 M | - | -10.17 % | $ 12.2 K | ||
|
Cerevel Therapeutics Holdings
CERE
|
-33.6 M | - | - | $ 7.29 B | ||
|
Compugen Ltd.
CGEN
|
-5.05 M | $ 2.04 | -2.39 % | $ 183 M | ||
|
Akouos
AKUS
|
-92.9 M | - | 0.23 % | $ 488 M | ||
|
Adaptimmune Therapeutics plc
ADAP
|
-119 M | - | -15.15 % | $ 60.3 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
469 M | $ 26.57 | 2.51 % | $ 1.29 B | ||
|
Coherus BioSciences
CHRS
|
-101 M | $ 2.26 | 9.7 % | $ 213 M | ||
|
Amneal Pharmaceuticals
AMRX
|
2.28 B | $ 13.59 | 1.46 % | $ 4.2 B | ||
|
Celldex Therapeutics
CLDX
|
-24.5 M | $ 26.72 | 3.09 % | $ 1.72 M | ||
|
AIkido Pharma
AIKI
|
-1.04 M | - | 1.93 % | $ 17.4 M | ||
|
Albireo Pharma
ALBO
|
-239 M | - | -0.23 % | $ 916 M | ||
|
CureVac N.V.
CVAC
|
-783 M | - | - | $ 867 M | ||
|
Acer Therapeutics
ACER
|
-2.08 M | - | 2.71 % | $ 14 M | ||
|
Alpine Immune Sciences
ALPN
|
-63.9 M | - | - | $ 2.17 B |